Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy

SIMPLE SUMMARY: The use of immunotherapeutic agents significantly improved stage-IV melanoma patients’ overall progression-free survival. To identify patients who do not benefit from immunotherapy, both clinical parameters and experimental biomarkers such as radiomics are currently being evaluated....

Descripción completa

Detalles Bibliográficos
Autores principales: Peisen, Felix, Hänsch, Annika, Hering, Alessa, Brendlin, Andreas S., Afat, Saif, Nikolaou, Konstantin, Gatidis, Sergios, Eigentler, Thomas, Amaral, Teresa, Moltz, Jan H., Othman, Ahmed E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221470/
https://www.ncbi.nlm.nih.gov/pubmed/35740659
http://dx.doi.org/10.3390/cancers14122992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221470/
https://www.ncbi.nlm.nih.gov/pubmed/35740659
http://dx.doi.org/10.3390/cancers14122992

Ejemplares similares